These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 25830296)
61. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Traish AM; Hassani J; Guay AT; Zitzmann M; Hansen ML J Sex Med; 2011 Mar; 8(3):872-84. PubMed ID: 21176115 [TBL] [Abstract][Full Text] [Related]
62. Androgenetic alopecia and current methods of treatment. Bienová M; Kucerová R; Fiurásková M; Hajdúch M; Koláŕ Z Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):5-8. PubMed ID: 15818439 [TBL] [Abstract][Full Text] [Related]
63. Androgenetic alopecia: an update. Kaliyadan F; Nambiar A; Vijayaraghavan S Indian J Dermatol Venereol Leprol; 2013; 79(5):613-25. PubMed ID: 23974579 [TBL] [Abstract][Full Text] [Related]
64. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745 [TBL] [Abstract][Full Text] [Related]
65. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183 [TBL] [Abstract][Full Text] [Related]
66. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies. Whiting DA Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540 [TBL] [Abstract][Full Text] [Related]
67. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. D'Amico AV; Roehrborn CG Lancet Oncol; 2007 Jan; 8(1):21-5. PubMed ID: 17196507 [TBL] [Abstract][Full Text] [Related]
68. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing]. Wolff H; Kunte C MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972 [TBL] [Abstract][Full Text] [Related]
69. Assessing finasteride-associated sexual dysfunction using the FAERS database. Gupta AK; Carviel J; MacLeod MA; Shear N J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1069-1075. PubMed ID: 28300347 [TBL] [Abstract][Full Text] [Related]
70. Therapeutic maintenance effect of finasteride 1 mg every other month regimen in androgenetic alopecia and study on the difference in response to finasteride treatment: A prospective cohort study. Kim KH; Kwon SH; Sim WY; Lew BL J Dermatol; 2024 Apr; 51(4):552-557. PubMed ID: 38293734 [TBL] [Abstract][Full Text] [Related]
71. Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. Yoshitake T; Takeda A; Ohki K; Inoue Y; Yamawaki T; Otsuka S; Akimoto M; Nemoto M; Shimakura Y; Sato A J Dermatol; 2015 Jul; 42(7):735-8. PubMed ID: 25903108 [TBL] [Abstract][Full Text] [Related]
72. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Keene S; Goren A Dermatol Ther; 2011; 24(2):296-300. PubMed ID: 21410621 [TBL] [Abstract][Full Text] [Related]
73. Follow-up of 1 mg finasteride treatment of male pattern baldness-difference between clinical trials and private office follow-up: influences on prescribing habits evaluated. Rapaport MJ Dermatol Surg; 2004 May; 30(5):761-3. PubMed ID: 15099321 [TBL] [Abstract][Full Text] [Related]
74. Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss. Basaria S; Jasuja R; Huang G; Wharton W; Pan H; Pencina K; Li Z; Travison TG; Bhawan J; Gonthier R; Labrie F; Dury AY; Serra C; Papazian A; O'Leary M; Amr S; Storer TW; Stern E; Bhasin S J Clin Endocrinol Metab; 2016 Dec; 101(12):4669-4680. PubMed ID: 27662439 [TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. Tanglertsampan C J Med Assoc Thai; 2012 Oct; 95(10):1312-6. PubMed ID: 23193746 [TBL] [Abstract][Full Text] [Related]
76. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Price VH; Roberts JL; Hordinsky M; Olsen EA; Savin R; Bergfeld W; Fiedler V; Lucky A; Whiting DA; Pappas F; Culbertson J; Kotey P; Meehan A; Waldstreicher J J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):768-76. PubMed ID: 11050579 [TBL] [Abstract][Full Text] [Related]
77. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698 [TBL] [Abstract][Full Text] [Related]
78. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. Haber RS; Gupta AK; Epstein E; Carviel JL; Foley KA J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1393-1397. PubMed ID: 30835851 [TBL] [Abstract][Full Text] [Related]
79. Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays. Chen L; Wang J; Mouser G; Li YC; Marcovici G Phytother Res; 2016 Jun; 30(6):1016-20. PubMed ID: 26990224 [TBL] [Abstract][Full Text] [Related]
80. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Pirozzi Farina F; Pischedda A Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]